Overview

* Teladoc Q2 revenue falls 2% to $631.9 mln, but beats analysts' expectations, per LSEG data

* Adjusted EBITDA down 23% to $69.3 mln, also beating expectations

* Co retired $550.6 mln in convertible notes, secured $300 mln credit facility

Outlook

* Teladoc expects full-year 2025 revenue of $2.501 bln to $2.548 bln

* Company projects full-year adjusted EBITDA of $263 mln to $294 mln

* Teladoc anticipates Q3 2025 revenue between $614 mln and $636 mln

* Company forecasts Q3 2025 adjusted EBITDA of $56 mln to $70 mln

Result Drivers

* INTEGRATED CARE GROWTH - Integrated Care segment revenue increased 4% year-over-year, driven by disciplined execution and strategic investments

* BETTERHELP DECLINE - BetterHelp segment revenue fell 9% year-over-year, reflecting challenges in the direct-to-consumer market

* CREDIT FACILITY - Co secured a $300 mln credit facility to enhance financial flexibility, per CEO Chuck Divita

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $631.90 $622.70

Revenue mln mln (23

Analysts

)

Q2 EPS -$0.19

Q2 Net -$32.66

Income mln

Q2 Beat $69.31 $63.50

Adjusted mln mln (22

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 22 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy."

* Wall Street's median 12-month price target for Teladoc Health Inc ( TDOC ) is $8.38, about 2.1% above its July 28 closing price of $8.20

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)